OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes research articles, reviews, communications and technical notes, etc. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8.5 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).
Pharmacogenetics and Chronic Pain
Submission Deadline: November 30, 2020 (Open) Submit Now
Ana M Peiró, MD, PhD
Neuropharmacology on Pain and Functional Diversity (NED), Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;
Clinical Pharmacology Unit, Department of Health of Alicante-General Hospital, Alicante, Spain;
Professor, Clinical Pharmacology Department. Universidad Miguel Hernandez, Alicante, Spain.
Research Interests: Pharmacogenetics; chronic pain; genes; pain treatment; genetic biomarker; genetic variability; pain management
About This Topic
Genome-wide association studies and candidate gene findings suggest that genetic approaches may help choose the most appropriate drug and dosage while preventing adverse drug reactions. This is the field that addresses Precision Medicine in opioid use evaluating variations in the DNA sequence that could be responsible for different individual analgesic response. We review potential gene biomarkers with best overall convergent functional evidence for opioid use in pain management. Polymorphisms can modify pharmacodynamics (i.e. mu opioid receptor, OPRM1) and pharmacokinetics (i.e. CYP2D6 phenotypes) pathways altering opioid effectiveness, consumption, side effects or even more, prescription opioid use dependence vulnerability. This review provides a summary these candidate variants for the translation of genotype into clinically useful information in pain medicine.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.